Sangamo Therapeutics (NASDAQ:SGMO) Receives Sector Perform Rating from Royal Bank of Canada

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “sector perform” rating restated by investment analysts at Royal Bank of Canada in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $2.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 134.19% from the company’s current price.

A number of other research firms have also recently issued reports on SGMO. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Monday, January 27th. Wells Fargo & Company cut their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Jefferies Financial Group dropped their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Truist Financial lowered their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $5.17.

Sangamo Therapeutics Stock Down 15.4 %

Shares of SGMO traded down $0.16 on Tuesday, hitting $0.85. The company’s stock had a trading volume of 6,237,729 shares, compared to its average volume of 7,613,174. The firm has a market capitalization of $178.18 million, a price-to-earnings ratio of -1.14 and a beta of 1.49. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The firm’s fifty day moving average price is $1.10 and its 200-day moving average price is $1.41.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million. As a group, equities analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. E Fund Management Co. Ltd. purchased a new stake in Sangamo Therapeutics during the fourth quarter worth $25,000. JPMorgan Chase & Co. grew its position in Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 21,793 shares during the period. PNC Financial Services Group Inc. grew its position in Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 25,000 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Sangamo Therapeutics in the fourth quarter valued at approximately $28,000. Finally, Shelton Wealth Management LLC purchased a new position in Sangamo Therapeutics during the fourth quarter valued at $29,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.